Author

J. Cherfils-Vicini

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

L. Seguin· 2 shared P. Hofman· 2 shared A. Ghinet· 1 shared B. Ryffel· 1 shared C. C. Feral· 1 shared C. Delannoy· 1 shared C. Delarasse· 1 shared C. Duranton· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

L. Seguin

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A ganglioside-based senescence-associated immune checkpoint

C. Iltis, L. Seguin, L. Cervera, L. Duret, T. Hamidouch, S. Kunz, O. Croce, C. Delannoy, Y. Guerardel, F. Allain, L. Moudombi, P. Hofman, E. Cosson, J. Guglielmi, T. Pourcher, , J. Cherfils-Vicini

This paper identifies GD3 as a senescence-associated immune checkpoint that suppresses NK cell-mediated clearance of senescent cells, showing that targeting GD3 can enhance anti-fibrotic effects in a mouse model.

bioRxiv · Apr 23, 2021 · PreprintImmunology

Small-molecule P2RX7 activator sensitizes tumor to immunotherapy and vaccinates mouse against tumor re-challenge

L. Douguet, S. Janho dit hreich, J. Benzaquen, l. seguin, T. Juhel, X. Dezitter, C. Duranton, B. Ryffel, J. Kanellopoulos, C. Delarasse, N. Renault, C. Furman, G. Homerin, C. Feral, J. Cherfils-Vicini, , V. Vouret-Craviari

The paper develops a P2RX7 activator that enhances immunotherapy efficacy and provides long-term tumor protection in mice.

bioRxiv · Nov 19, 2020 · PreprintCancer Biology